Netris Pharma’s lead product was awarded €1.2 million Eurostar grant to make an antibody therapeutic to treat arthritis and metastatic bone cancer pain.
Turbine will provide its machine learning platform to better understand which cancer types and patient population stand to benefit most from treatment by Cancer Research’s drug candidate.
After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.
BioNTech and Ryvu Therapeutics will collaborate to develop oncology programs, with the pair announcing that they will work together as part of a multi-target research collaboration.
Partnership between Massive Bio and Azra AI extends clinical care teams bandwidth to place cancer patients in trials while eliminating unconscious bias.
For its two lead oncology programs, the company will pursue “market-based pricing”, moving away from plans to “dramatically lower prices” for treatments.
Massive Bio partners with Perthera.ai to improve cancer clinical trial enrolment through the use of AI technology to connect oncologists and patients with biomarker-based therapy options.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
The gathering, convened by patient advocacy group Fight Colorectal Cancer, responded to President Biden’s call to improve screening and treatment options.
Clinical Trial Navigator, from AmerisourceBergen, is designed to help sponsors pair with oncology practices to boost patient recruitment opportunities.
The health care system and analytics company are joining on the ASAP study, a program that constitutes a five-year commitment to advancing cancer solutions.
The latest indepth report from the AI-centric analytics provider reveals nearly half of US cancer clinical studies enroll no Latino patient participants.
The academic research center has adopted the life science technology company’s cloud-based platform for cancer research, drug discovery, and clinical trials.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The pharmaceutical firm will work with the health tech company to create a digital therapeutic intended for patients dealing with a breast cancer diagnosis.
The sponsorship from Janssen Pharmaceutical Companies will be used by the cancer support network to boost diversity in Phase I and Phase 2 clinical trials.
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
A new survey reveals the majority of the general public thinks more cancer research is in order, but many are reluctant to pitch in to the effort financially.
During the upcoming BIO International Convention, experts from CerFlux, the MD Anderson Cancer Center, and Aga Khan University will weigh in with insights.
The cancer trial-matching company is partnering with MPN Research Foundation to help match patients with a group of rare blood cancers to clinical trials.
The US agency has approved Enhertu for patients diagnosed with HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
The one-year-old organization is giving $50m USD in grants to encourage scientists from five cancer research centers to work together on cancer solutions.
The partnership among three research and data specialists is aimed at creating a global database to support faster development of novel cancer treatments.
Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.
The recruitment tech specialist has added oncology clinical studies to its marketplace, providing sponsors with a larger pool of patients to choose from.
The US Department of Health and Human Service’s Office of Research Integrity has uncovered evidence that Toni Brand committed fraud in a number of reports.
The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.
The Pancreatic Cancer Action Network has engaged five new clinical trial sites in the US, which will aid in evaluation of Novartis’ investigational therapy.
The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.
Patient-centric company Belong.life has developed an app designed to inform cancer research by offering a holistic view of the lives of people with cancer.
A leader from the eClinical solutions provider talks about the unique considerations that cancer studies have at every stage, and how technological solutions can help address them.
The drug discovery firm will work with the Dean Felsher Laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
The company’s analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
The precision medicine company is joining with decentralized trial specialist Curebase to bring its cancer studies to a more diverse group of patients.
The oncology center’s Marie-Josée and Henry R. Kravis Cancer Ecosystems Project is intended to elevate the next generation of preclinical cancer research.
On World Cancer Day, the Union for International Cancer Control is launching a three-year campaign with the goal to improve cancer care around the globe.
Blue Note Therapeutics has announced the status has been granted to BNT200, a device to treat anxiety and depression in acute myeloid leukemia patients.
The researchers, in studying how polyps morph into colorectal cancer, have set a path for improved surveillance of the disease, harnessing precision medicine.
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.